TP53 and myelodysplastic syndrome: ALX148 plus azacitidine: in 5 newly diagnosed higher-risk MDS patients (all had TP53 mutation), 1 reached marrow CR, 2 reached cytogenetic response; in 5 relapsed/refractory MDS patients, 2 reached marrow CR.